1081MO Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma
P.A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ana Arance(Hospital Clínic de Barcelona), C. Robert(Institut Gustave Roussy), Filip De Vos(University Medical Center Utrecht), Samuel Murray(Memorial Sloan Kettering Cancer Center), Dirk Schadendorf(National Center for Tumor Diseases), M. Gil Martín(Institut Català d'Oncologia), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), V. Gambardella(INCLIVA Health Research Institute), Emily Han-Chung Hsiue(Howard Hughes Medical Institute), Steven R. Sloan(Boston Children's Hospital), Sarah Moody(Wellcome Sanger Institute), Jordi Rodon(Centre de Recerca en Sanitat Animal), V. Moreno Garcia(Hospital Universitario Fundación Jiménez Díaz), M. De Miguel(Hospital Universitario La Paz), Rahman Jamal(Centre Hospitalier de l’Université de Montréal), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Belén Ruíz(Novartis (China)), Martin McLaughlin(Queen's University Belfast)
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k